Rituximab biosimilar - Lupin
Latest Information Update: 14 Jan 2022
At a glance
- Originator Lupin
- Class Anti-inflammatories; Antineoplastics; Antirheumatics; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Skin disorder therapies; Urologics; Vascular disorder therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 28 Mar 2018 No recent reports of development identified for clinical-Phase-Unknown development in Rheumatoid-arthritis in India (IV, Infusion)
- 03 Jan 2018 Lupin completes a clinical trial in Rheumatoid arthritis in India, before January 2018 (IV) (CTRI2015-01-005398)
- 29 Aug 2016 Preclinical trials in Rheumatoid arthritis in India (IV) before August 2016